IPI-549

• CAT Number: I002208
• CAS Number: 1693758-51-8
• Molecular Formula: C₃₀H₂₄N₈O₂
• Molecular Weight: 528.56
• Purity: ≥95%
• Target: 16 nM (PI3Kγ), 3.2 μM (PI3Kα), 3.5 μM (PI3Kβ), >8.4 μM (PI3Kδ)[1]
• Solubility: DMSO
• Storage: Store at -20°C
• IUPAC Name: 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• InChI: InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
• InChIKey: XUMALORDVCFWKV-IBGZPJMESA-N
• SMILES: CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N

IPI-549 is produced by Infinity Pharmaceuticals. The mechanism of action is to block the PI3 kinase-gamma ( PI3Kγ ) molecule in inhibitory cells, which can be used as a cell biology reagent. IPI-549 is a selective phosphoinositide 3-kinase ( PI3Kγ ) inhibitor. PI3Kγ inhibitors can be used to develop potential treatments for inflammatory and autoimmune diseases.

Reference

[1]. Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7(9):862-7.